The precedent is that it's a requirement before progressing to the P3 trial.
As per the AGM meeting presentation (and roadshow presos) the meeting is a FDA Type B meeting for the end of Phase 2 for Phelan McDermid syndrome, to review and agree the next steps and requirements for Phase 3 trials.
Type B detail here: https://www.fda.gov/media/72253/download
Neuren Media and Analyst Coverage, page-1352
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.65 |
Change
-0.110(0.80%) |
Mkt cap ! $1.744B | |||
| Open | High | Low | Value | Volume |
| $13.86 | $13.95 | $13.46 | $6.774M | 494.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1736 | $13.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.80 | 2854 | 3 |
View Market Depth
| Last trade - 16.10pm 16/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |